Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 12/20 | 0.56 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21429006 | 1.00 | TACR2 (0.56) | TACR2ROR1IDO1HDAC3HDAC1 | |
| SCHEMBL31717765 | 0.90 | ROR1 (0.52) | TACR2ROR1HDAC3HDAC1HDAC8 | |
| SCHEMBL3120523 | 0.88 | TACR2 (0.65) | TACR2IDO1 | |
| SCHEMBL14952799 | 0.88 | TACR2 (0.65) | TACR2IDO1 | |
| SCHEMBL29701949 | 0.88 | TACR2 (0.65) | TACR2IDO1 | |
| SCHEMBL29701929 | 0.88 | TACR2 (0.65) | TACR2IDO1 | |
| SCHEMBL14952762 | 0.88 | IDO1 (0.62) | TACR2IDO1HDAC3HDAC1HDAC8 | |
| SCHEMBL29717101 | 0.88 | IDO1 (0.62) | TACR2IDO1HDAC3HDAC1HDAC8 | |
| SCHEMBL19479695 | 0.86 | TACR2 (0.51) | TACR2HDAC3HDAC1HDAC8 | |
| SCHEMBL29420247 | 0.85 | KDM4A (0.56) | ROR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | UNIVERSITY OF WARWICK (GB) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | NGLY1, MAX, PTMA | TACR2 1556/4885ROR1 214/4885IDO1 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.